pharma · Hereditary Angioedema · Influenza · BCRX
Biocryst
NovaPharmaNews editorial coverage mentioning Biocryst — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- München, DE
- Founded
- 1986
- Employees
- 6
- Programs
- 37
- Drugs
- 17
- Patents
- 72
News & analysis
NovaPharmaNews articles mentioning Biocryst — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Biocryst — regulatory, clinical, and market analysis.
BioCryst’s New ORLADEYO Data Adds Real-World HAE Evidence
BioCryst Pharmaceuticals is presenting new clinical data and real-world evidence for ORLADEYO (berotralstat) in hereditary angioedema. The update matters because it expands the evidence base around an FDA-approved oral prophylactic option for adults and pediatric patients 2 years and older.
European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio
BioCryst Pharmaceuticals has secured a significant European deal for its rare disease drug, Navenibart, bolstering its portfolio and reaffirming its 2026 financial outlook. This strategic move positions the company for expanded market presence and potential revenue growth.